Role of the new bioimpedance monitoring device (Seca®) in assessing dry weight in hemodialysis patients.

Kimio Watanabe, Yugo Ito, Takuya Fujimaru, Masahiko Nagahama, Fumika Taki, Masaaki Nakayama

Clinical and experimental nephrology 2022 May

filter terms:

In recent years, bioimpedance analysis has come to be widely used in clinical practice for dialysis patients, but there is not sufficient consensus on its significance. We aimed to examine the merits of performing bioimpedance analysis in addition to conventional evaluation methods for dry weight such as measuring human atrial natriuretic peptide (hANP), blood pressure, and cardiothoracic ratio in patients on chronic hemodialysis. Body composition of 78 hemodialysis patients was performed by using a new and more accurate segmental multifrequency bioimpedance analysis device (Seca® medical body composition analyzer 525, Seca GmbH & Co. KG, Hamburg, Germany). Laboratory data including hANP at post-dialysis and demographic profile were collected. Statistical analysis was performed with SPSS software. Mean age of the patients was 66.9 ± 12.6 years and 80.8% were males. Mean value of hANP and the ratio of extracellular water to total body water (ECW/TBW) were 61.4 ± 36.4 pg/mL and 46.1 ± 3.9%, respectively. The calculated ECW/TBW cutoff point for hANP > 50 pg/mL was 45.0%, with sensitivity of 74.4% and specificity of 64.7%. Patients with an ECW/TBW of more than 45% and hANP value of > 50 pg/mL had a higher blood pressure and cardiothoracic ratio on chest X-ray examination. Our results suggest that the ratio of extracellular water to total body water of more than 45% and hANP value of ≥ 50 pg/mL were overhydrated in chronic hemodialysis patients. Whether monitoring levels of these parameters has a role in the outcome including patients' survival and cardiovascular events requires further study. © 2022. Japanese Society of Nephrology.

Citation

Kimio Watanabe, Yugo Ito, Takuya Fujimaru, Masahiko Nagahama, Fumika Taki, Masaaki Nakayama. Role of the new bioimpedance monitoring device (Seca®) in assessing dry weight in hemodialysis patients. Clinical and experimental nephrology. 2022 May;26(5):460-465